tasisulam + erlotinib

Tasisulam + erlotinib is an experimental combination regimen investigated for the treatment of advanced solid tumors. **Tasisulam** (LY573636) is a small molecule anticancer agent that induces apoptosis through the intrinsic mitochondrial pathway and possesses antiangiogenic properties; it is characterized by high albumin binding, which necessitates specific exposure-based dosing strategies. **Erlotinib** is an orally active tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). The combination was evaluated in Phase 1b multi-arm clinical trials to assess safety, tolerability, and pharmacokinetics in patients with advanced malignancies, including non-small-cell lung cancer (NSCLC). However, the clinical development of tasisulam was ultimately terminated by Eli Lilly following unfavorable results in other late-stage trials.

Other names

tasisulam sodium + erlotinibLY573636 sodium + erlotinibtasisulam + erlotinib hydrochloride